WilliamJSandbornMD
Gastroenterology • San Diego, CAProfessor, Medicine, UC San Diego Sch. of Medicine
Dr. Sandborn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 W Arbor Dr
San Diego, CA 92103Phone+1 800-926-8273
Summary
- I am a board-certified gastroenterologist with an expertise in the management of ulcerative colitis and Crohns disease. Currently, I direct the Inflammatory Bowel Disease (IBD) Center at UC San Diego Health. The IBD Center is a large clinical research unit devoted to the conduct of clinical trials in inflammatory bowel disease, where I supervise a multi-investigator team of physicians, research fellows, nurses, and study coordinators.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Gastroenterology, 1990 - 1993
Loma Linda University Health Education ConsortiumResidency, Internal Medicine, 1987 - 1990
Loma Linda University School of MedicineClass of 1987
Certifications & Licensure
CA State Medical License 1988 - 2025
AZ State Medical License 1993 - 2013
MN State Medical License 1990 - 2011- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2014
- Top Doctors:San Diego Area Castle Connolly, 2013
- Top Doctors:Southern California Castle Connolly, 2012
- Join now to see all
Clinical Trials
- Open-Label Adalimumab for Ulcerative Colitis Patients Start of enrollment: 2006 Oct 01
Publications & Presentations
PubMed
- 150 citationsEfficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative ColitisWilliam J. Sandborn, Subrata Ghosh, Julián Panés, Stefan Schreiber, Geert R. D'Haens
Gastroenterology. 2020-06-01 - 184 citationsOzanimod as induction and maintenance therapy for ulcerative colitis.William J. Sandborn, Brian G. Feagan, Geert R. D'Haens, Douglas C. Wolf, Igor Jovanovic
The New England Journal of Medicine. 2021-09-30 - 125 citationsAnti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trialSeverine Vermeire, William J. Sandborn, Silvio Danese, Xavier Hébuterne, Bruce Salzberg
Lancet. 2017-07-08
Journal Articles
- Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumLeah Katta, Robert Hirten, Shannon Chang, Dana Lukin, Edward V Loftus, David Faleck, Arun Swaminath, William J Sandborn, Sashidhar Varma Sagi, Sunanda Kane, Prianka Ch..., Nature
- Comparison of Multiplex Gastrointestinal Pathogen Panel and Conventional Stool Testing for Evaluation of Diarrhea in Patients with Inflammatory Bowel DiseasesWaseem Ahmad, Daniel Bouland, Nghia H Nguyen, David T Pride, Siddharth Singh, Parambir S Dulai, William J Sandborn, Brigid S Boland, Digestive Diseases and Sciences
- Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis ConceptsParambir S Dulai, William J Sandborn, Brigid S Boland, Derek R Patel, Inflammatory Bowel Diseases
- Join now to see all
Authored Content
- Progression of Elderly-Onset IBDFebruary 2020
Press Mentions
Organoids Derived from Gut Stem Cells Reveal Two Distinct Molecular Subtypes of Crohn’s DiseaseSeptember 26th, 2024- Organoids Derived from Gut Stem Cells Reveal Two Distinct Molecular Subtypes of Crohn’s DiseaseSeptember 26th, 2024
- Pivotal Years: Abivax’s Obefazimod Faces Phase III TestDecember 26th, 2022
- Join now to see all
Professional Memberships
- Fellow
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
